Neuromed strikes major Merck deal

Article Abstract:

Neuromed Pharmaceuticals Ltd. a spin off of British Columbia University has struck a drug research deal valued at up to $500 million (U.S) with giant Merck &Co. Inc., the biggest collaboration in Canada. Details of the deal are presented.

Alliances, partnerships, British Columbia, Alliances and partnerships, Merck & Company Inc.

---

Generic drug makers target new proposal

Article Abstract:

The new food and drug regulation-eight year data protection for brand names, adopted by the federal government of Canada is opposed by the generic drug makers as it would hamper the efforts of the generic drug makers.

Government domestic functions, Public affairs, Interpretation and construction, Political activity, Medical policy, Health policy

---

Does toxic fish hold medical marvels?

Article Abstract:

The details on the testing of tetrodotoxin drug by Wex Pharmaceuticals Inc. to solve chronic pain in central nervous system are examined.

Product information, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Testing, Analgesics, Tetrodotoxin (Medication)

Similar abstracts:

• Abstracts: Firms cautious over hot quarter. Ottawa open to China in small doses. A year after Fiorina's exit, Hurd makes his mark at HP
• Abstracts: Montreal port head lauds CP Ships deal. British firm snaps up Canadian itravel2000
• Abstracts: CanWest serves notice it plans to sever ties with the Canadian Press. CanWest spinoff could net the firm about $770-million
• Abstracts: 'Warning shot' on trusts set for budget. OECD warns hot economy could tip into overdrive. Confidence plummets to post-9/11 levels
• Abstracts: Legendary ad man French, sans cigar. Advertisers prepare to pull plug on hockey. CEO defends Tims U.S. push

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.